Gold nanoparticles modified screen-printed immunosensor for cancer biomarker HER2 determination based on anti HER2 bioconjugates
Human epidermal growth factor receptor 2 (HER2) is a biomarker of breast cancer plays a major role in the proliferation of breast cancer cells. The determination of HER2 concentration is one of the ways of early detection of breast cancer. In this study we have developed a label free immunosensor fo...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Tagungsbericht |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | |
| container_title | |
| container_volume | 2049 |
| creator | Hartati, Yeni Wahyuni Nurdjanah, Dewina Wyantuti, Santhy Anggraeni, Anni Gaffar, Shabarni |
| description | Human epidermal growth factor receptor 2 (HER2) is a biomarker of breast cancer plays a major role in the proliferation of breast cancer cells. The determination of HER2 concentration is one of the ways of early detection of breast cancer. In this study we have developed a label free immunosensor for the detection of HER2 using an anti HER2-gold nanoparticles (GNP) bioconjugates. Anti HER2-GNP bioconjugates synthesized by adding anti HER2 on the GNPs that already reacted with APTMS and PEG-NHS-Maleimide. GNP-APTMS characterized using FTIR and cyclic voltammetry with a potassium ferrisianide system. The anti HER2-GNP bioconjugates immobilized on the screen printed carbon electrode-GNP (SPCE-GNP) surface with covalent bonding systems (amine coupling). The result of this study showed FTIR spectra that anti HER2-GNP bioconjugates successfully synthesized. The cyclic voltammograms of GNP-SPCE without and with anti HER2-GNP bioconjugates showed the increase of fericyanide redox pair peak current from 51.946 µA to 121.891 µA. The anti HER2 bioconjugates binds HER2 then the fericyanide peak current decreases in proportion with the addition of HER2. Optimal response of current signal was generated at concentration 5.0 µg/mL anti HER2 and the incubation time of anti HER2-GNP was 1 hour. Limit of detection of HER2 from developed immunosensor is 1.02 x 10−2 ng/mL. |
| doi_str_mv | 10.1063/1.5082456 |
| format | Conference Proceeding |
| fullrecord | <record><control><sourceid>proquest_scita</sourceid><recordid>TN_cdi_proquest_journals_2156233093</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2156233093</sourcerecordid><originalsourceid>FETCH-LOGICAL-c328t-fdb59acbf4578a5dbfdc6e47062221e8f7cc3754cdbc18fcd60c25fbf5c61a2a3</originalsourceid><addsrcrecordid>eNp9kE9LAzEQxYMoWKsHv8GCN2Fr_myy26OU2goFQRS8LdlJIqndZE2ygjc_utEWvHkY5g38Zob3ELokeEawYDdkxnFDKy6O0IRwTspaEHGMJhjPq5JW7OUUncW4xZjO67qZoK-V36nCSecHGZKFnY5F75U1VqsiQtDalUOwLuXR9v3ofNQu-lCYXCAd6FB01vcyvGW1Xj7SQumkQ2-dTNa7opMxr2YhXbJ7IPPg3XZ8lUnHc3Ri5C7qi0Ofoue75dNiXW4eVveL200JjDapNKrjcwmdqXjdSK46o0DoqsaCUkp0Y2oAVvMKVAekMaAEBspNZzgIIqlkU3S1vzsE_z7qmNqtH4PLL1tKuKCM4TnL1PWeimDTr4E2u8_uPluC25-EW9IeEv4P_vDhD2wHZdg316B_fw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>conference_proceeding</recordtype><pqid>2156233093</pqid></control><display><type>conference_proceeding</type><title>Gold nanoparticles modified screen-printed immunosensor for cancer biomarker HER2 determination based on anti HER2 bioconjugates</title><source>AIP Journals Complete</source><creator>Hartati, Yeni Wahyuni ; Nurdjanah, Dewina ; Wyantuti, Santhy ; Anggraeni, Anni ; Gaffar, Shabarni</creator><contributor>Fatmawati, Sri ; Purnomo, Adi Setyo ; Kusumawati, Yuly ; Juwono, Hendro ; Kurniawan, Fredy</contributor><creatorcontrib>Hartati, Yeni Wahyuni ; Nurdjanah, Dewina ; Wyantuti, Santhy ; Anggraeni, Anni ; Gaffar, Shabarni ; Fatmawati, Sri ; Purnomo, Adi Setyo ; Kusumawati, Yuly ; Juwono, Hendro ; Kurniawan, Fredy</creatorcontrib><description>Human epidermal growth factor receptor 2 (HER2) is a biomarker of breast cancer plays a major role in the proliferation of breast cancer cells. The determination of HER2 concentration is one of the ways of early detection of breast cancer. In this study we have developed a label free immunosensor for the detection of HER2 using an anti HER2-gold nanoparticles (GNP) bioconjugates. Anti HER2-GNP bioconjugates synthesized by adding anti HER2 on the GNPs that already reacted with APTMS and PEG-NHS-Maleimide. GNP-APTMS characterized using FTIR and cyclic voltammetry with a potassium ferrisianide system. The anti HER2-GNP bioconjugates immobilized on the screen printed carbon electrode-GNP (SPCE-GNP) surface with covalent bonding systems (amine coupling). The result of this study showed FTIR spectra that anti HER2-GNP bioconjugates successfully synthesized. The cyclic voltammograms of GNP-SPCE without and with anti HER2-GNP bioconjugates showed the increase of fericyanide redox pair peak current from 51.946 µA to 121.891 µA. The anti HER2 bioconjugates binds HER2 then the fericyanide peak current decreases in proportion with the addition of HER2. Optimal response of current signal was generated at concentration 5.0 µg/mL anti HER2 and the incubation time of anti HER2-GNP was 1 hour. Limit of detection of HER2 from developed immunosensor is 1.02 x 10−2 ng/mL.</description><identifier>ISSN: 0094-243X</identifier><identifier>EISSN: 1551-7616</identifier><identifier>DOI: 10.1063/1.5082456</identifier><identifier>CODEN: APCPCS</identifier><language>eng</language><publisher>Melville: American Institute of Physics</publisher><subject>Biomarkers ; Breast cancer ; Cancer ; Gold ; Growth factors ; Immunosensors ; Nanoparticles ; Synthesis</subject><ispartof>AIP conference proceedings, 2018, Vol.2049 (1)</ispartof><rights>Author(s)</rights><rights>2018 Author(s). Published by AIP Publishing.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c328t-fdb59acbf4578a5dbfdc6e47062221e8f7cc3754cdbc18fcd60c25fbf5c61a2a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://pubs.aip.org/acp/article-lookup/doi/10.1063/1.5082456$$EHTML$$P50$$Gscitation$$H</linktohtml><link.rule.ids>309,310,314,776,780,785,786,790,4498,23909,23910,25118,27901,27902,76126</link.rule.ids></links><search><contributor>Fatmawati, Sri</contributor><contributor>Purnomo, Adi Setyo</contributor><contributor>Kusumawati, Yuly</contributor><contributor>Juwono, Hendro</contributor><contributor>Kurniawan, Fredy</contributor><creatorcontrib>Hartati, Yeni Wahyuni</creatorcontrib><creatorcontrib>Nurdjanah, Dewina</creatorcontrib><creatorcontrib>Wyantuti, Santhy</creatorcontrib><creatorcontrib>Anggraeni, Anni</creatorcontrib><creatorcontrib>Gaffar, Shabarni</creatorcontrib><title>Gold nanoparticles modified screen-printed immunosensor for cancer biomarker HER2 determination based on anti HER2 bioconjugates</title><title>AIP conference proceedings</title><description>Human epidermal growth factor receptor 2 (HER2) is a biomarker of breast cancer plays a major role in the proliferation of breast cancer cells. The determination of HER2 concentration is one of the ways of early detection of breast cancer. In this study we have developed a label free immunosensor for the detection of HER2 using an anti HER2-gold nanoparticles (GNP) bioconjugates. Anti HER2-GNP bioconjugates synthesized by adding anti HER2 on the GNPs that already reacted with APTMS and PEG-NHS-Maleimide. GNP-APTMS characterized using FTIR and cyclic voltammetry with a potassium ferrisianide system. The anti HER2-GNP bioconjugates immobilized on the screen printed carbon electrode-GNP (SPCE-GNP) surface with covalent bonding systems (amine coupling). The result of this study showed FTIR spectra that anti HER2-GNP bioconjugates successfully synthesized. The cyclic voltammograms of GNP-SPCE without and with anti HER2-GNP bioconjugates showed the increase of fericyanide redox pair peak current from 51.946 µA to 121.891 µA. The anti HER2 bioconjugates binds HER2 then the fericyanide peak current decreases in proportion with the addition of HER2. Optimal response of current signal was generated at concentration 5.0 µg/mL anti HER2 and the incubation time of anti HER2-GNP was 1 hour. Limit of detection of HER2 from developed immunosensor is 1.02 x 10−2 ng/mL.</description><subject>Biomarkers</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Gold</subject><subject>Growth factors</subject><subject>Immunosensors</subject><subject>Nanoparticles</subject><subject>Synthesis</subject><issn>0094-243X</issn><issn>1551-7616</issn><fulltext>true</fulltext><rsrctype>conference_proceeding</rsrctype><creationdate>2018</creationdate><recordtype>conference_proceeding</recordtype><recordid>eNp9kE9LAzEQxYMoWKsHv8GCN2Fr_myy26OU2goFQRS8LdlJIqndZE2ygjc_utEWvHkY5g38Zob3ELokeEawYDdkxnFDKy6O0IRwTspaEHGMJhjPq5JW7OUUncW4xZjO67qZoK-V36nCSecHGZKFnY5F75U1VqsiQtDalUOwLuXR9v3ofNQu-lCYXCAd6FB01vcyvGW1Xj7SQumkQ2-dTNa7opMxr2YhXbJ7IPPg3XZ8lUnHc3Ri5C7qi0Ofoue75dNiXW4eVveL200JjDapNKrjcwmdqXjdSK46o0DoqsaCUkp0Y2oAVvMKVAekMaAEBspNZzgIIqlkU3S1vzsE_z7qmNqtH4PLL1tKuKCM4TnL1PWeimDTr4E2u8_uPluC25-EW9IeEv4P_vDhD2wHZdg316B_fw</recordid><startdate>20181214</startdate><enddate>20181214</enddate><creator>Hartati, Yeni Wahyuni</creator><creator>Nurdjanah, Dewina</creator><creator>Wyantuti, Santhy</creator><creator>Anggraeni, Anni</creator><creator>Gaffar, Shabarni</creator><general>American Institute of Physics</general><scope>8FD</scope><scope>H8D</scope><scope>L7M</scope></search><sort><creationdate>20181214</creationdate><title>Gold nanoparticles modified screen-printed immunosensor for cancer biomarker HER2 determination based on anti HER2 bioconjugates</title><author>Hartati, Yeni Wahyuni ; Nurdjanah, Dewina ; Wyantuti, Santhy ; Anggraeni, Anni ; Gaffar, Shabarni</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c328t-fdb59acbf4578a5dbfdc6e47062221e8f7cc3754cdbc18fcd60c25fbf5c61a2a3</frbrgroupid><rsrctype>conference_proceedings</rsrctype><prefilter>conference_proceedings</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Biomarkers</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Gold</topic><topic>Growth factors</topic><topic>Immunosensors</topic><topic>Nanoparticles</topic><topic>Synthesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hartati, Yeni Wahyuni</creatorcontrib><creatorcontrib>Nurdjanah, Dewina</creatorcontrib><creatorcontrib>Wyantuti, Santhy</creatorcontrib><creatorcontrib>Anggraeni, Anni</creatorcontrib><creatorcontrib>Gaffar, Shabarni</creatorcontrib><collection>Technology Research Database</collection><collection>Aerospace Database</collection><collection>Advanced Technologies Database with Aerospace</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hartati, Yeni Wahyuni</au><au>Nurdjanah, Dewina</au><au>Wyantuti, Santhy</au><au>Anggraeni, Anni</au><au>Gaffar, Shabarni</au><au>Fatmawati, Sri</au><au>Purnomo, Adi Setyo</au><au>Kusumawati, Yuly</au><au>Juwono, Hendro</au><au>Kurniawan, Fredy</au><format>book</format><genre>proceeding</genre><ristype>CONF</ristype><atitle>Gold nanoparticles modified screen-printed immunosensor for cancer biomarker HER2 determination based on anti HER2 bioconjugates</atitle><btitle>AIP conference proceedings</btitle><date>2018-12-14</date><risdate>2018</risdate><volume>2049</volume><issue>1</issue><issn>0094-243X</issn><eissn>1551-7616</eissn><coden>APCPCS</coden><abstract>Human epidermal growth factor receptor 2 (HER2) is a biomarker of breast cancer plays a major role in the proliferation of breast cancer cells. The determination of HER2 concentration is one of the ways of early detection of breast cancer. In this study we have developed a label free immunosensor for the detection of HER2 using an anti HER2-gold nanoparticles (GNP) bioconjugates. Anti HER2-GNP bioconjugates synthesized by adding anti HER2 on the GNPs that already reacted with APTMS and PEG-NHS-Maleimide. GNP-APTMS characterized using FTIR and cyclic voltammetry with a potassium ferrisianide system. The anti HER2-GNP bioconjugates immobilized on the screen printed carbon electrode-GNP (SPCE-GNP) surface with covalent bonding systems (amine coupling). The result of this study showed FTIR spectra that anti HER2-GNP bioconjugates successfully synthesized. The cyclic voltammograms of GNP-SPCE without and with anti HER2-GNP bioconjugates showed the increase of fericyanide redox pair peak current from 51.946 µA to 121.891 µA. The anti HER2 bioconjugates binds HER2 then the fericyanide peak current decreases in proportion with the addition of HER2. Optimal response of current signal was generated at concentration 5.0 µg/mL anti HER2 and the incubation time of anti HER2-GNP was 1 hour. Limit of detection of HER2 from developed immunosensor is 1.02 x 10−2 ng/mL.</abstract><cop>Melville</cop><pub>American Institute of Physics</pub><doi>10.1063/1.5082456</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0094-243X |
| ispartof | AIP conference proceedings, 2018, Vol.2049 (1) |
| issn | 0094-243X 1551-7616 |
| language | eng |
| recordid | cdi_proquest_journals_2156233093 |
| source | AIP Journals Complete |
| subjects | Biomarkers Breast cancer Cancer Gold Growth factors Immunosensors Nanoparticles Synthesis |
| title | Gold nanoparticles modified screen-printed immunosensor for cancer biomarker HER2 determination based on anti HER2 bioconjugates |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T23%3A45%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_scita&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=proceeding&rft.atitle=Gold%20nanoparticles%20modified%20screen-printed%20immunosensor%20for%20cancer%20biomarker%20HER2%20determination%20based%20on%20anti%20HER2%20bioconjugates&rft.btitle=AIP%20conference%20proceedings&rft.au=Hartati,%20Yeni%20Wahyuni&rft.date=2018-12-14&rft.volume=2049&rft.issue=1&rft.issn=0094-243X&rft.eissn=1551-7616&rft.coden=APCPCS&rft_id=info:doi/10.1063/1.5082456&rft_dat=%3Cproquest_scita%3E2156233093%3C/proquest_scita%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2156233093&rft_id=info:pmid/&rfr_iscdi=true |